Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats

Free Radical Research

Volumn 42, Issue 3, 2008, Pages 226-236

  Sicard, Pierre ^a   Delemasure, Stéphanie ^a   Korandji, Claudia ^a   Grand, Anabelle Segueira Le ^b   Lauzier, Benjamin ^a   Guilland, Jean Claude ^a   Duvillard, Laurence ^c   Zeller, Marianne ^a   Cottin, Yves ^a,c   Vergely, Catherine ^a   Rochette, Luc ^a  

^a Laboratory of Experimental Cardiovascular Pathophysiology and Pharmacology   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Cytokines; Hypertension; Leukocytes; NAD(P)H oxidase; Statins

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; INFLAMMATION; LEUKOCYTE; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE; BLOOD PRESSURE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-4; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PYRIMIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

RATTUS;

EID: 41049113282     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760701885380     Document Type: Article

References (67)

1. Touyz, RM (2005) Molecular and cellular mechanisms in vascular injury in hypertension: Role of angiotensin II-editorial review. Curr Opin Nephrol Hypertens, 14, pp. 125-131.
2. de Champlain, J., Wu, R., Girouard, H., Karas, M., Midaoui, A El, Laplante, MA and Wu, L. (2004) Oxidative stress in hypertension. Clin Exp Hypertens, 26, pp. 593-601.
3. Virdis, A. and Schiffrin, EL (2003) Vascular inflammation: A role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens, 12, pp. 181-187.
4. Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339, pp. 572-575.
5. Kielstein, JT, Boger, RH, Bode-Boger, SM, Schaffer, J., Barbey, M., Koch, KM and Frolich, JC (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol, 10, pp. 594-600.
6. Johnstone, MT, Creager, SJ, Scales, KM, Cusco, JA, Lee, BK and Creager, MA (1993) Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation, 88, pp. 2510-2516.
7. Beckman, J., Beckman, T., Chen, J., Marshall, P. and Freeman, B. (1990) Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxyde. Proc Natl Acad Sci USA, 87, pp. 1620-1624.
8. Sanz-Rosa, D., Oubina, MP, Cediel, E., Heras, N de Las, Vegazo, O., Jimenez, J., Lahera, V. and Cachofeiro, V. (2005) Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol, 288, pp. H111-H115.
9. Ni, W., Kitamoto, S., Ishibashi, M., Usui, M., Inoue, S., Hiasa, K., Zhao, Q., Nishida, K., Takeshita, A. and Egashira, K. (2004) Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol, 24, pp. 534-539.
10. Yasunari, K., Maeda, K., Nakamura, M. and Yoshikawa, J. (2002) Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension, 39, pp. 777-780.
11. Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109, pp. III39-III43.
12. Egashira, K., Koyanagi, M., Kitamoto, S., Ni, W., Kataoka, C., Morishita, R., Kaneda, Y., Akiyama, C., Nishida, KI, Sueishi, K. and Takeshita, A. (2000) Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: Blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. Faseb J, 14, pp. 1974-1978.
13. Ando, H., Takamura, T., Ota, T., Nagai, Y. and Kobayashi, K. (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther, 294, pp. 1043-1046.
14. Sposito, AC and Chapman, MJ (2002) Statin therapy in acute coronary syndromes: Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol, 22, pp. 1524-1534.
15. Stalker, TJ, Lefer, AM and Scalia, R. (2001) A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol, 133, pp. 406-412.
16. Sicard, P., Lauzier, B., Oudot, A., Busseuil, D., Collin, B., Duvillard, L., Moreau, D., Vergely, C. and Rochette, L. (2005) A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats]. Arch Mal Coeur Vaiss, 98, pp. 804-808.
17. Susic, D., Varagic, J., Ahn, J., Slama, M. and Frohlich, ED (2003) Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol, 42, pp. 1091-1097.
18. Otto, A., Fontaine, D., Fontaine, J. and Berkenboom, G. (2005) Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol, 46, pp. 177-184.
19. Mooradian, AD, Haas, MJ, Batejko, O., Hovsepyan, M. and Feman, SS (2005) Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes, 54, pp. 2977-2982.
20. Korandji, C., Zeller, M., Guilland, JC, Vergely, C., Sicard, P., Duvillard, L., Gambert, P., Moreau, D., Cottin, Y. and Rochette, L. (2007) Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction. Clin Biochem, 21:2, pp. 173-180.
21. Kim, CH and Vaziri, ND (2005) Hypertension promotes integrin expression and reactive oxygen species generation by circulating leukocytes. Kidney Int, 67, pp. 1462-1470.
22. Sicard, P., Acar, N., Gregoire, S., Lauzier, B., Bron, AM, Creuzot-Garcher, C., Bretillon, L., Vergely, C. and Rochette, L. (2007) Influence of rosuvastatin on the NAD(P)H oxidase activity in the retina and electroretinographic response of spontaneously hypertensive rats. Br J Pharmacol, 151, pp. 979-986.
23. Sicard, P., Oudot, A., Guilland, JC, Moreau, D., Vergely, C. and Rochette, L. (2006) Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive rats. Vascul Pharmacol, 45, pp. 112-121.
24. Sagar, S., Kallo, IJ, Kaul, N., Ganguly, NK and Sharma, BK (1992) Oxygen free radicals in essential hypertension. Mol Cell Biochem, 111, pp. 103-108.
25. Dzau, VJ (2001) Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension, 37, pp. 1047-1052.
26. Boger, RH (2006) Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann Med, 38, pp. 126-136.
27. Ito, A., Egashira, K., Narishige, T., Muramatsu, K. and Takeshita, A. (2001) Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J, 65, pp. 775-778.
28. Boger, RH, Bode-Boger, SM, Tsao, PS, Lin, PS, Chan, JR and Cooke, JP (2000) An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol, 36, pp. 2287-2295.
29. Wells, SM and Holian, A. (2007) Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol, 36, pp. 520-528.
30. MacAllister, RJ, Parry, H., Kimoto, M., Ogawa, T., Russell, RJ, Hodson, H., Whitley, GS and Vallance, P. (1996) Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol, 119, pp. 1533-1540.
31. Wakino, S., Hayashi, K., Tatematsu, S., Hasegawa, K., Takamatsu, I., Kanda, T., Homma, K., Yoshioka, K., Sugano, N. and Saruta, T. (2005) Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res, 28, pp. 255-262.
32. Charo, IF and Taubman, MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res, 95, pp. 858-866.
33. Libby, P. (2002) Inflammation in atherosclerosis. Nature, 420, pp. 868-874.
34. Libby, P. and Ridker, PM (2004) Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med, 116, p. 9S.
35. Matsumori, A. and Sasayama, S. (2001) The role of inflammatory mediators in the failing heart: Immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev, 6, pp. 129-136.
36. Ishibashi, M., Hiasa, K., Zhao, Q., Inoue, S., Ohtani, K., Kitamoto, S., Tsuchihashi, M., Sugaya, T., Charo, IF, Kura, S., Tsuzuki, T., Ishibashi, T., Takeshita, A. and Egashira, K. (2004) Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res, 94, pp. 1203-1210.
37. Parissis, JT, Venetsanou, KF, Kalantzi, MV, Mentzikof, DD and Karas, SM (2000) Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol, 85, pp. 777-779.
38. Tedgui, A. and Mallat, Z. (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 86, pp. 515-581.
39. Coccia, EM, Stellacci, E., Marziali, G., Weiss, G. and Battistini, A. (2000) IFN-gamma and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation. Int Immunol, 12, pp. 977-985.
40. Murata, Y., Shimamura, T. and Hamuro, J. (2002) The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol, 14, pp. 201-212.
41. Ozturk, H., Ozturk, H., Buyukbayram, H. and Tuncer, MC (2006) The effects of exogenous interleukin-4 on hypoxia-induced lung injury. Pediatr Surg Int, 22, pp. 197-201.
42. Michel, JB, Sayah, S., Guettier, C., Nussberger, J., Philippe, M., Gonzalez, MF, Carelli, C., Galen, FX, Menard, J. and Corvol, P. (1990) Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation, 81, pp. 1899-1910.
43. Dang, A., Zheng, D., Wang, B., Zhang, Y., Zhang, P., Xu, M., Liu, G. and Liu, L. (1999) The role of the renin-angiotensin and cardiac sympathetic nervous systems in the development of hypertension and left ventricular hypertrophy in spontaneously hypertensive rats. Hypertens Res, 22, pp. 217-221.
44. Kobori, H., Ozawa, Y., Suzaki, Y. and Nishiyama, A. (2005) Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol, 16, pp. 2073-2080.
45. Griendling, KK and Ushio-Fukai, M. (2000) Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept, 91, pp. 21-27.
46. Harrison, D., Griendling, KK, Landmesser, U., Hornig, B. and Drexler, H. (2003) Role of oxidative stress in atherosclerosis. Am J Cardiol, 91, pp. 7A-11A.
47. Nava, E., Noll, G. and Luscher, TF (1995) Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation, 91, pp. 2310-2313.
48. Chou, TC, Yen, MH, Li, CY and Ding, YA (1998) Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension, 31, pp. 643-648.
49. Cheng, PY, Chen, JJ and Yen, MH (2004) The expression of heme oxygenase-1 and inducible nitric oxide synthase in aorta during the development of hypertension in spontaneously hypertensive rats. Am J Hypertens, 17, pp. 1127-1134.
50. Kimura, T., Iwase, M., Kondo, G., Watanabe, H., Ohashi, M., Ito, D. and Nagumo, M. (2003) Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol, 3, pp. 1519-1528.
51. Brzozowski, T., Konturek, PC, Konturek, SJ, Kwiecien, S., Sliwowski, Z., Pajdo, R., Duda, A., Ptak, A. and Hahn, EG (2003) Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin. Int J Colorectal Dis, 18, pp. 320-329.
52. Shen, K., Sung, KL, Whittemore, DE, DeLano, FA, Zweifach, BW and Schmid-Schonbein, GW (1995) Properties of circulating leukocytes in spontaneously hypertensive rats. Biochem Cell Biol, 73, pp. 491-500.
53. Dorffel, Y., Latsch, C., Stuhlmuller, B., Schreiber, S., Scholze, S., Burmester, GR and Scholze, J. (1999) Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension, 34, pp. 113-117.
54. Rodriguez-Iturbe, B., Zhan, CD, Quiroz, Y., Sindhu, RK and Vaziri, ND (2003) Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension, 41, pp. 341-346.
55. Wu, R., Millette, E., Wu, L. and de Champlain, J. (2001) Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens, 19, pp. 741-748.
56. Ito, H., Torii, M. and Suzuki, T. (1995) Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive rats. Clin Exp Hypertens, 17, pp. 803-816.
57. Friese, RS, Mahboubi, P., Mahapatra, NR, Mahata, SK, Schork, NJ, Schmid-Schonbein, GW and O'Connor, DT (2005) Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. Am J Hypertens, 18, pp. 633-652.
58. Terzoli, L., Mircoli, L., Raco, R. and Ferrari, AU (2005) Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol, 46, pp. 310-315.
59. Yin, QF and Xiong, Y. (2005) Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol, 45, pp. 525-532.
60. Habibi, J., Whaley-Connell, A., Qazi, MA, Hayden, MR, Cooper, SA, Tramontano, A., Thyfault, J., Stump, C., Ferrario, C., Muniyappa, R. and Sowers, JR (2007) Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology, 148, pp. 2181-2188.
61. Wassmann, S., Laufs, U., Muller, K., Konkol, C., Ahlbory, K., Baumer, AT, Linz, W., Bohm, M. and Nickenig, G. (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 22, pp. 300-305.
62. Wagner, AH, Kohler, T., Ruckschloss, U., Just, I. and Hecker, M. (2000) Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 20, pp. 61-69.
63. Kwak, B., Mulhaupt, F., Myit, S. and Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat Med, 6, pp. 1399-1402.
64. Youssef, S., Stuve, O., Patarroyo, JC, Ruiz, PJ, Radosevich, JL, Hur, EM, Bravo, M., Mitchell, DJ, Sobel, RA, Steinman, L. and Zamvil, SS (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 420, pp. 78-84.
65. Blanco-Colio, LM, Munoz-Garcia, B., Martin-Ventura, JL, Lorz, C., Diaz, C., Hernandez, G. and Egido, J. (2003) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation, 108, pp. 1506-1513.
66. Frostegard, J., Ulfgren, AK, Nyberg, P., Hedin, U., Swedenborg, J., Andersson, U. and Hansson, GK (1999) Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis, 145, pp. 33-43.
67. Aktas, O., Waiczies, S., Smorodchenko, A., Dorr, J., Seeger, B., Prozorovski, T., Sallach, S., Endres, M., Brocke, S., Nitsch, R. and Zipp, F. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med, 197, pp. 725-733.